Ocuphire Pharma Past Earnings Performance
Past criteria checks 0/6
Ocuphire Pharma has been growing earnings at an average annual rate of 21.3%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 85.7% per year.
Key information
21.3%
Earnings growth rate
33.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 85.7% |
| Return on equity | -20.0% |
| Net Margin | -52.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch
May 02
Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Mar 15Analysts Just Shaved Their Ocuphire Pharma, Inc. (NASDAQ:OCUP) Forecasts Dramatically
May 20Ocuphire Pharma, Inc. Just Beat Revenue Estimates By 42%
Apr 02We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate
Jan 27We Think Ocuphire Pharma (NASDAQ:OCUP) Needs To Drive Business Growth Carefully
Oct 08Ocuphire completes patient enrollment for phase 2 trial of diabetic retinopathy treatment
Sep 08Ocuphire Pharma GAAP EPS of -$0.25 beats by $0.08
Aug 12Ocuphire extends IP rights for lead candidate with new U.S. patent
Aug 03Ocuphire gets new U.S. patent for its oral drug candidate APX3330 for use in diabetics
Jun 29We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate
Jun 24Is Ocuphire Pharma (NASDAQ:OCUP) In A Good Position To Invest In Growth?
Mar 22Here's Why We're Not Too Worried About Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation
Oct 08Ocuphire Pharma: An Undervalued Ophthalmic Play
Aug 05Ocuphire Pharma inks licensing deal for RX-3117 with Processa Pharma
Jun 17Ocuphire Pharma (NASDAQ:OCUP) Is In A Good Position To Deliver On Growth Plans
Jun 11Ocuphire drops 11% on $15M at-the money direct offering
Jun 04Ocuphire Pharma EPS beats by $0.36
May 07Do Institutions Own Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares?
Feb 08Ocuphire concludes enrollment in late-stage trial of Nyxol for dilated pupil condition
Jan 06Ocuphire Pharma launches late-stage study of Nyxol in night vision disturbances
Jan 05Revenue & Expenses BreakdownBeta
How Ocuphire Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 19 | -10 | 12 | 17 |
| 30 Sep 23 | 57 | 29 | 11 | 0 |
| 30 Jun 23 | 45 | 19 | 10 | 0 |
| 31 Mar 23 | 42 | 19 | 8 | 0 |
| 31 Dec 22 | 40 | 18 | 7 | 14 |
| 30 Sep 22 | 0 | -22 | 7 | 0 |
| 30 Jun 22 | 0 | -22 | 7 | 0 |
| 31 Mar 22 | 1 | -24 | 8 | 0 |
| 31 Dec 21 | 1 | -57 | 8 | 0 |
| 30 Sep 21 | 1 | -69 | 8 | 0 |
| 30 Jun 21 | 0 | -66 | 7 | 0 |
| 31 Mar 21 | 0 | -61 | 4 | 0 |
| 31 Dec 20 | 0 | -25 | 3 | 0 |
| 30 Sep 20 | 0 | -8 | 2 | 1 |
| 30 Jun 20 | 0 | -9 | 2 | 2 |
| 31 Mar 20 | 0 | -8 | 2 | 2 |
| 31 Dec 19 | 0 | -6 | 2 | 2 |
Quality Earnings: OCUP is currently unprofitable.
Growing Profit Margin: OCUP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OCUP is unprofitable, but has reduced losses over the past 5 years at a rate of 21.3% per year.
Accelerating Growth: Unable to compare OCUP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OCUP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: OCUP has a negative Return on Equity (-20.01%), as it is currently unprofitable.